<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did KZR's operating expenses drop sharply in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/8/2025 10:27pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">The decrease in Kezar Life Sciences' operating expenses in Q4 2024 can be attributed to **reduced clinical trial costs** related to the PALIZADE and PORTOLA trials. 

The company's General and Administrative (G&amp;A) expenses decreased by $0.3 million to $5.5 million for the fourth quarter of 2024 compared to $5.8 million in the same period of the previous year. This reduction in expenses, despite the absence of revenue, indicates a more efficient management of resources by the company.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:C,comeFrom:"AInvestShareLink",events:[],answerSource:h}],fetch:{},error:i,state:{sharePreviewModule:{loadJgySuccess:j,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:h,cache_builder:a,reply_action:"Answer",execute_mode:v,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did KZR's operating expenses drop sharply in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did KZR's operating expenses drop sharply in Q4 2024?\",\"user_id\":\"dp55602598\",\"user_name\":\"\",\"trace_id\":\"ac3ace18-9628-4769-81fe-341f6864a53f\",\"session_id\":\"ac3ace18-9628-4769-81fe-341f6864a53f\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:D,title:E,summary:F,full_summary:"SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported positive topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH) and reported fourth quarter and year end 2024 financial results. “We are pleased to announce these exciting results from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH,” said Chris Kirk, CEO and co-founder of Kezar. “We are encouraged by the safety and efficacy data in this difficult-to-treat patient population, specifically durable and steroid-sparing remissions experienced by patients treated with zetomipzomib. We are eager to work with the FDA Division of Hepatology and Nutrition to remove the partial clinical hold and align on an appropriate trial design to demonstrate the clinical benefit of zetomipzomib in AIH. I’d like to thank the team at Kezar, the physicians and staff at our clinical trial sites, and most importantly, the patients and their caregivers, for their participation, sacrifice and hard work.” “I am impressed by the totality of efficacy and safety data from the PORTOLA study,” said Gideon Hirschfield, Chair of Autoimmune Liver Disease Research and Director of the Francis Family Liver Clinic, at the Toronto General Hospital. “Zetomipzomib represents a potent and targeted therapy for patients, and I believe these results will positively contribute to the design of a registrational trial of zetomipzomib in AIH, where patients are in need of better treatment options.” PORTOLA is a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH that are insufficiently responding to standard of care or have relapsed",url:G,image_url:a,video_url:a,publish_time:H,search_extra_info:{search_burial_info:{id:w,uid:I,ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]}}},simhash:"2ae32161e7c4481f",msg_id:w}}],answer_chain_name:M,agent_mode:N,native_answer:a,come_from:a,text_answer:C,trace_id:e,cost:10708,event_names:a,question:d,fallback_type:O,input_type:P,fall_back_reason:{fall_back_type:O,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:e,first_return_cost:3180,cache_type:"no_cache",question_id:e,transfer_question:d,signal_type:"ON_COMPLETE",start_time:x,remote_svc:h,slots:[],answer_type:v,user_id:r,skill_name:y},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:e,session_id:e,user_id:r,question:d,source:h,raw_question:d,version:"3.4.1",action_name:y,nlu:{entity:[{type:Q,value:"KZR.O",market:R}]},output_time:x,deep_research:c,deep_thinking:c,agent_mode:N},extra:{}},{answer_path:k,section:{id:l,info_texts:["Thinking"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:k,section:{id:l,info_texts:["Querying Stock: KZR Latest Report Period"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:"Querying Stock",action_input:"KZR Latest Report Period",thought:T}},{answer_path:k,section:{id:l,info_texts:["Searching Web: Why was KZR Operating Expenses Decrease in Q4 2024"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:S},logs:[],extra:{action:"Searching Web",action_input:"Why was KZR Operating Expenses Decrease in Q4 2024",thought:T}},{answer_path:f,section:{id:U,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:U,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:k,section:{id:l,info_texts:["Generating Answer"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:f,section:{id:s,info_texts:[],show_type:t,voice_txt:"The",text_answer:V,rich_text:V,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:2000,info_texts:[],show_type:t,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:G,image_url:a,video_url:a,title:E,summary:F,index:D,publish_time:H,search_id:w,search_uid:I,search_ab:{scene_id:J,layer_exp:[{layer_id:K,exp_id:L}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:s,info_texts:[],show_type:t,voice_txt:". \n\n",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"KZR",market_id:R,name:X,domain:Q},pos:16,section_id:s,txt:X,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:f,section:{id:s,info_texts:[],show_type:t,voice_txt:"'s",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:k,section:{id:l,info_texts:["Completed"],show_type:m,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"1eebd32458a7d55a3c4936ac104b8a3b",item_type:g,item_name:n,rec_info:Z}},{display_text:o,query_text:o,trace_info:{item_id:"eb1f8ad02c4167e9b39b55fe34a1b50b",item_type:g,item_name:o,rec_info:_}},{display_text:p,query_text:p,trace_info:{item_id:"f6a066b9414382d8f5b94831caa0880b",item_type:g,item_name:p,rec_info:$}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:j,type:"1",display2:c,url:a}},request_config:[{source_type:aa,related_name:ab}],puuid:A,tag:a,category:"custom",uuid:ac}],global:{urp_static_data:[{name:ab,value:{status_code:j,columns:[{type:q,index_name:ad,key:ad},{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag},{type:q,index_name:ah,key:ah}],datas:[{send_text:n,item_type:g,rec_info:Z,display_text:n,rec_reason:a},{send_text:o,item_type:g,rec_info:_,display_text:o,rec_reason:a},{send_text:p,item_type:g,rec_info:$,display_text:p,rec_reason:a}],dataSize:aa,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:ai,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:u,"min-height":"100%",position:aj,height:u},isMaterial:c,id:ai,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:j,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:B,componentUuid:ac,script:[{name:ak,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:B,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:B},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:u,position:aj,height:u},isMaterial:b,_id:19,id:ak,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:al,voice_txt:a,tracking_info:{},uuid:A},order:{is_auto:c,render_for:al,chart_type:"command",puuid:A}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:y,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:v,answer_chain_name:M},is_deep_research:c,deep_thinking:c,create_time:1746714431419},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:i,docsData:[],quoteData:i},tplType:"question"},events:am,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:am,client_ip:a,question:d,user_id:r,user_name:a,trace_id:e,session_id:e,source:h,input_type:P}}],userId:r,userName:a,startTime:x,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:i,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:j,traceTableData:i,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-kzrs-operating-expenses-drop-sharply-in-q4-2024-f323af\u002F",config:{_app:{basePath:an,assetsPath:an,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Why did KZR's operating expenses drop sharply in Q4 2024?","ac3ace18-9628-4769-81fe-341f6864a53f","other\u002FopenAnswer","llm_generated","ths_ainvest_lite_web",null,0,"progress\u002Fsearching_for",1000,"searching_for","🔎 How do analysts view KZR's cost management efforts in their recent reports?","👮 What is the impact of the drop in operating expenses on KZR's profit margins?","📊 How does the current operating expense ratio compare to KZR's historical performance?","STR","dp55602598",2001,"rich_text","auto","agent","ff5f2fe2d5502596_4",1746714420712,"inspect stocks","signal","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","The decrease in Kezar Life Sciences' operating expenses in Q4 2024 can be attributed to **reduced clinical trial costs** related to the PALIZADE and PORTOLA trials. \n\nThe company's General and Administrative (G&A) expenses decreased by $0.3 million to $5.5 million for the fourth quarter of 2024 compared to $5.8 million in the same period of the previous year. This reduction in expenses, despite the absence of revenue, indicates a more efficient management of resources by the company.",2,"Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results","The decrease was partially offset by the increased clinical trial costs related to the PALIZADE and PORTOLA trials. General and administrative (G&A) expenses for the fourth quarter of 2024 decreased by $0.3 million to $5.5 million compared to $5.8 million in the fourth quarter of 2023. Full year G&A...","https:\u002F\u002Fwww.businesswire.com\u002Fnews\u002Fhome\u002F20250325918238\u002Fen\u002FKezar-Life-Sciences-Announces-Positive-Topline-Results-from-the-PORTOLA-Phase-2a-Trial-Evaluating-Zetomipzomib-for-the-Treatment-of-Patients-with-Autoimmune-Hepatitis-AIH-and-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results","2024-12-30","ff5f2fe2d5502596","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","thinking","The user wants to analyze why KZR's operating expenses decreased significantly in Q4 2024. I should focus on the latest report period to obtain the relevant data and information. I will use FinQuery for the data mentioned above; use Search for the reason behind corresponding figures.",999,"The decrease in Kezar Life Sciences' operating expenses in Q4 2024 can be attributed to **reduced clinical trial costs** related to the PALIZADE and PORTOLA trials[^2]",". \n\nThe company","Kezar Life Sciences","'s General and Administrative (G&A) expenses decreased by $0.3 million to $5.5 million for the fourth quarter of 2024 compared to $5.8 million in the same period of the previous year[^2]. This reduction in expenses, despite the absence of revenue, indicates a more efficient management of resources by the company.","2+679_496_21_554+0+0+ac3ace18-9628-4769-81fe-341f6864a53f+1eebd32458a7d55a3c4936ac104b8a3b+llm_generated+aimeTagAnalysis+0+0.022265756502747536+1","2+679_496_21_554+0+0+ac3ace18-9628-4769-81fe-341f6864a53f+eb1f8ad02c4167e9b39b55fe34a1b50b+llm_generated+aimeTagAnalysis+0+0.016826776787638664+2","2+679_496_21_554+0+0+ac3ace18-9628-4769-81fe-341f6864a53f+f6a066b9414382d8f5b94831caa0880b+llm_generated+aimeTagAnalysis+0+0.013971079140901566+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>